Hologic (NASDAQ:HOLX) (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.
Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions. A landmark transaction was the 2012 acquisition of Gen-Probe, which expanded the company’s leadership in molecular diagnostics and infectious disease testing. Over the years, Hologic has invested heavily in research and development, bringing advances such as rapid COVID-19 molecular tests and minimally invasive surgical technologies to market.
The company serves customers in more than 100 countries across North America, Europe, Latin America, Asia-Pacific and the Middle East. Its products are distributed to hospitals, diagnostic laboratories, imaging centers and physician offices, supported by manufacturing facilities and regional offices around the world. Through partnerships with health systems and public health agencies, Hologic’s diagnostic platforms play a critical role in early disease detection and population health screening programs.
Hologic is led by President and Chief Executive Officer Jan Verstreken, who has overseen the company’s strategic initiatives since 2022. Under his leadership, Hologic continues to prioritize innovation in women’s health and expand its global footprint, with ongoing efforts to streamline operations, strengthen supply chains and accelerate development of next-generation diagnostic and imaging technologies.
